welcome, you're not logged in. Home | Login | Contact us   
Search center

Print this to PDF...Print...


The drug discovery process is long and expensive...... our aim is to shorten this process by producing high-quality, hit-like, lead-like and drug-like compounds, which generate quality valuable data from screening programmes.

The Maybridge Screening collection consists of over 53,000 organic compounds, largely produced by us at Maybridge. These are individually designed compounds, produced by innovative synthetic techniques, based on over 45 years of experience in heterocyclic chemistry.

Now available off the shelf the entire Maybridge screening collection of over 53,000 compounds pre-plated as 1umol dry films in 96 well plate format. Exceptional diversity and outstanding value!

The pre-plated HitFinderTM Collection consists of 14,400 Maybridge Screening Compounds, selected to represent the diversity of the Maybridge Screening Collection using a clustering algorithm based on standard Daylight Fingerprints and Tanimoto similarity, and is conveniently supplied as dry films in Matrix 96 shallow well plates or 384 well microplates.



An independent study carried out by McGregor and Pallai comparing the diversity of 10 commercially available libraries and the Available Chemicals Directory (ACD) showed that out of the libraries that were produced in-house, Maybridge had the most diverse library i.e. the most singletons (clusters with one member), and the highest number of clusters. (Ref. The Journal of Chemical Information and Computer Sciences 1997,37,443-448)


"Of the ~400,000 pharmacophores* in the world drug index ~87% are expressed by the Maybridge Screening collection." (*Calculations carried out by Oxford Molecular using Chem-X definition, i.e. triplets of H-bond acceptors, H-bond donors, aromatic ring centres and positive nitrogen atoms.The compounds in the Maybridge collection generally obey Lipinski's** "rule of five" and so demonstrate good ADME (absorption, distribution, metabolism and excretion) profiles, which makes them ideal candidates for development beyond the initial Screening assay.


Maybridge Screening Collection

< 5 H-bond donors

99.7% <5

<10 h-bond="" acceptors="">

99.8% <10

cLog P <5>

mean log P 3.23, 94% in range -0.11 to 6.3

Mol. Weight <500>

mean mol. weight 325, 95% in range 150-500

See the evidence here

**Lipinski , C.A. , Lombardo, F., Dominy, B.W. and Feeney, P.J. (1996). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 23 3-25.

ADME Calculations

HIA good/poor cutoff set at 40% (J. Pharm. Sci., 2001, 90, p749
BBB BBB+ >= -0.2,  BBB- <=-0.5, BBB+/- borderline (Eur. J. Med. Chem., 2001, 36, p719 & J. Med. Chem., 2000, 43, p2204)


Analysis of Screening compounds is by appropriate methodology, selected from:

    • Nuclear Magnetic Resonance Spectroscopy (NMR)
    • Infra-Red Spectroscopy (FT-IR)
    • Liquid Chromatography-Mass Spectrometry (LC-MS)
    • High Performance Liquid Chromatography (HPLC)
    • Elemental Analysis
    • The purity of the Screening Collection, unless stated, is greater than 90% with a majority of compounds having a purity of 95%.
    • Reactive molecules are excluded in order to reduce the number of false positives. (click here for full details)



Typically, about 95% of the compounds in our collection are available in >5mg stock quantities and over 90% of the compounds are available in >50mg stock quantities. Indeed a large proportion of our collection is available in gram quantities; this means we can ensure a very high level of re-supply of originally tested compounds.


    • In 96 well plates at mass >=2µmol or >=0.5mg as powder, dry films or frozen DMSO solutions
    • In 96 or 384 well plates at mass > 0.1µmol or >0.01mg as dry films or frozen DMSO solutions.
    • In vials at mass >2µmol or 0.5mg as powder or DMSO solutions.

Maybridge can provide most major brands of plates/vials but is happy to use those supplied by customers on request.

Check out our Narrated PowerPoint presentation.


Thermo Fisher Scientific Inc